RecruitingHeart Failure With Reduced Ejection Fraction
A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction
Eligible age
18–100 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of HJB647 at two different doses in participants with chronic stable heart failure with reduced or mildly reduced ejection fraction (HFrEF/HFmrEF).
Sponsor: Novartis Pharmaceuticals
You may qualify if…
- ✓ Participants eligible for inclusion in this study must meet all of the following criteria:
- ✓ Men and women aged 18 years or older
- ✓ Stable NYHA functional class II-III
- ✓ LVEF \<50%
- ✓ NT-proBNP ≥600 pg/ml if in sinus rhythm or ≥900 pg/ml if in atrial fibrillation at screening
- ✓ On stable standard of care therapy with sacubitril/valsartan with a dose of at least 49/51 mg BID for at least 4 weeks before screening.
You may not qualify if…
- ✕ Participants will be deemed ineligible for inclusion if they meet any of the following exclusion criteria:
- ✕ Acute decompensated heart failure within 3 months prior to screening
- ✕ SBP \<105 mmHg at screening or baseline.
- ✕ Acute coronary syndrome, stroke, transient ischemic attack, cardiac, carotid or other major cardiovascular surgery, PCI, or carotid angioplasty within the 6 months prior to screening
- ✕ Hemodynamically significant mitral and/or aortic valve disease, or any prior valve replacement, except mitral regurgitation secondary to LV dilation at screening
- ✕ eGFR \<45 ml/min/1.73m2 at screening, as measured by the CKD-EPI formula
- ✕ BMI \>40 kg/m2
- ✕ Strong CYP3A4 inhibitors or inducers, sGC activators (vericiguat), PDE5 inhibitors, and nitroglycerin products
Where it's recruiting
Florida
Bradenton · Inverness · Jacksonville
Source: ClinicalTrials.gov · NCT07465653 · last updated 2026-04-15